Ignite Creation Date:
2024-05-19 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06415669
Status:
RECRUITING
Last Update Posted:
2024-05-29
First Post:
2024-04-27
Brief Title:
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in GastricGastroesophageal Junction Adenocarcinoma
Sponsor:
The First Affiliated Hospital of Xiamen University
Organization:
The First Affiliated Hospital of Xiamen University
Study Overview
Official Title:
A Study of Paclitaxel Albumin-bound Combined With Apatinib and Adebrelimab in the Treatment of Locally Advanced or Metastatic GastricGastroesophageal Junction Adenocarcinoma Following Previous Immunotherapy Progression
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the initial efficacy and safety of paclitaxel for injection albumin-bound in combination with apatinib mesylate and adebrelimab in the treatment of locally advanced or metastatic gastricgastroesophageal junction adenocarcinoma following the progression of previous immunotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None